Scale-up
Moving from early-stage development to larger manufacturing scales while maintaining process consistency and material continuity.
:quality(75))
How we support pharmaceutical development programmes
Support for organisations developing oligonucleotide therapeutics, siRNA, antisense oligonucleotides (ASOs), mRNA therapeutics and emerging RNA-based medicines from discovery through clinical development.
Who we support
Biotechnology organisations, therapeutic developers, formulation scientists and process development teams working on nucleic acid therapeutic programmes.
How we help
We support oligonucleotide and RNA therapeutic developers with phosphoramidites and solid supports, custom oligonucleotide synthesis, IVT enzymes, formulation development support and scalable manufacturing technologies. Drawing on decades of expertise in oligonucleotide chemistry, our teams help organisations address synthesis optimisation, process development, scale-up and supply continuity challenges from discovery through clinical development.
Related Applications
:quality(75))
:quality(75))
Oligo Synthesis
:quality(75))
Oligo Synthesis
:quality(75))
Reagent Components
:quality(75))
Oligo Synthesis
:quality(75))
Reagent Components
Why partner with LGC for pharmaceutical development programmes
Supporting drug development programmes with scalable materials, manufacturing expertise and scientific support.
:quality(75))
Customers
37,000+
Supporting scientific organisations worldwide
Countries
144
Serving customers across global markets
Featured Resources
Featured Resources
:quality(75))
:quality(75))
:quality(75))
Frequently asked questions
What materials do you supply for preclinical and clinical programmes?
LGC supplies phosphoramidites, solid supports, custom oligonucleotides, IVT enzymes, formulation components and other materials used in oligonucleotide and RNA therapeutic development and manufacturing.
What are your lead times for clinical supply?
Lead times depend on product type, specification requirements and manufacturing complexity. Early engagement helps ensure availability of critical materials and supports efficient programme planning.
What quantities can you manufacture?
Manufacturing scale depends on the specific therapeutic modality, process requirements and development stage. Our teams work with customers to identify materials, technologies and supply strategies that support programme progression from early development through larger-scale manufacturing activities.
How do you handle material changes mid-programme?
Material changes are evaluated through established change-control processes, with consideration given to product specifications, supply continuity and programme requirements to help minimise development disruption.
What are nucleic acid therapeutics?
Nucleic acid therapeutics are medicines designed to influence gene expression or cellular processes using RNA- or DNA-based molecules. These include antisense oligonucleotides (ASOs), siRNA, mRNA therapeutics, aptamers and emerging modalities such as circular RNA (circRNA).
What is involved in oligonucleotide therapeutic development?
Oligonucleotide therapeutic development typically includes sequence design, synthesis optimisation, analytical characterisation, process development, scale-up, manufacturing and formulation activities. Each stage requires consideration of product quality, manufacturability and clinical requirements.
Why is in vitro transcription important for mRNA therapeutics?
In vitro transcription (IVT) is the primary process used to produce mRNA molecules for therapeutic applications. Successful IVT workflows depend on high-quality enzymes, raw materials and optimised manufacturing processes to support RNA yield, integrity and scalability.
What is circular RNA (circRNA)?
Circular RNA (circRNA) is an emerging therapeutic modality characterised by a covalently closed structure. Ongoing research is evaluating its potential in therapeutic applications due to its stability and ability to support sustained protein expression compared with linear RNA molecules.
What challenges are associated with therapeutic delivery?
Effective delivery remains a major consideration in nucleic acid therapeutic development. Delivery technologies and molecular modifications are often used to help therapeutic molecules reach target tissues, improve cellular uptake and support therapeutic performance.
What are phosphoramidites and solid supports used for in oligonucleotide manufacturing?
Phosphoramidites and solid supports are fundamental raw materials used in solid-phase oligonucleotide synthesis. Their quality and consistency can influence manufacturing efficiency, product quality and scalability during therapeutic oligonucleotide development.
:quality(65))
Discuss your pharmaceutical development programme
Connect with our specialists to explore solutions supporting drug development, preclinical development, manufacturing scale-up and clinical progression.